---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-000520"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2024-01-12T23:59:59+00:00"
generated_at: "2026-06-07T00:04:49.993883+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Dermata shareholders approve warrant issuance and auditor ratification at special meeting

## Summary
- Issuance Proposal: 789,001 for, 5,008 against, 231 abstain, 485,871 broker non-votes — approved.
- Ratification of Moss Adams LLP as independent auditor for FY 2023: 1,269,895 for, 9,551 against, 665 abstain — approved.
- Adjournment Proposal: 788,925 for, 4,893 against, 422 abstain, 485,871 broker non-votes — approved.
- Special meeting held January 12, 2024; record date November 17, 2023 with 3,189,034 shares outstanding.

## SEC filing metadata
- accession: 0001654954-24-000520
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2024-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495424000520/0001654954-24-000520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495424000520/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-000520
- JSON: https://secwatch.observer/filing/0001654954-24-000520.json
- Plain text: https://secwatch.observer/filing/0001654954-24-000520.txt

## Key facts
- Shareholder Votes
  Dermata Therapeutics, Inc. shareholders approved The ratification of the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (Auditor Proposal) at the 2024-01-12 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-01-12
  source text: Proposal No. 2 : The Auditor Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 1,269,895 9,551 665 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495424000520/0001654954-24-000520-index.htm
- Shareholder Votes
  Dermata Therapeutics, Inc. shareholders approved The authorization for purposes of complying with Nasdaq Listing Rule 5635(d) of the issuance of shares of Common Stock underlying certain warrants (Issuance Proposal) at the 2024-01-12 meeting.
  - Outcome: passed
  - Meeting: 2024-01-12
  source text: Proposal No. 1 : The Issuance Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 789,001 5,008 231 485,871
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495424000520/0001654954-24-000520-index.htm
- Shareholder Votes
  Dermata Therapeutics, Inc. shareholders approved The approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies (Adjournment Proposal) at the 2024-01-12 meeting.
  - Outcome: passed
  - Meeting: 2024-01-12
  source text: Proposal No. 3 : The Adjournment Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 788,925 4,893 422 485,871
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495424000520/0001654954-24-000520-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.